| Literature DB >> 34248112 |
Cyndy Liu1, Tae Nakano-Tateno1, Motoyasu Satou1,2, Constance Chik1, Toru Tateno1.
Abstract
Pituitary adenomas are benign tumours that can cause an individual various clinical manifestations including tumour mass effects and/or the diverse effects of abnormal pituitary hormone secretion. Given the morbidity and limited treatment options for pituitary adenomas, there is a need for better biomarkers and treatment options. One molecule that is of specific interest is the signal transducer and activator of transcription 3 (STAT3), a transcription factor that plays a critical role in mediating cytokine-induced changes in gene expression. In addition, STAT3 controls cell proliferation by regulating mitochondrial activity. Not only does activation of STAT3 play a crucial role in tumorigenesis, including pituitary tumorigenesis, but a number of studies also demonstrate pharmacological STAT3 inhibition as a promising treatment approach for many types of tumours, including pituitary tumours. This review will focus on the role of STAT3 in different pituitary adenomas, in particular, growth hormone-producing adenomas and null cell adenomas. Furthermore, how STAT3 is involved in the cell proliferation and hormone regulation in pituitary adenomas and its potential role as a molecular therapeutic target in pituitary adenomas will be summarized.Entities:
Keywords: Biomarker; Pituitary adenomas; Signal transducer and activator of transcription 3 (STAT3)
Mesh:
Substances:
Year: 2021 PMID: 34248112 DOI: 10.1507/endocrj.EJ21-0106
Source DB: PubMed Journal: Endocr J ISSN: 0918-8959 Impact factor: 2.349